EUVIMEDEUVIMED entdecken
Crossref

Clozapine‐Associated Neutropenia Prevalence in a Large, Integrated Healthcare System

Jill L Nofziger iD, Andrea H Kline-Simon, Leah M Arnbrecht, Cimone Durojaiye, Matthew E Hirschtritt

Pharmacoepidemiology and Drug Safety · 2025

DOI: 10.1002/pds.70249 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Jill L Nofziger und 4 weiteren Autor:innen. Beteiligte Einrichtung: Regional Clinical Pharmacy Operations, Kaiser Permanente Northern California, Livermore, California, USA. Hauptthemen laut MEDLINE: Clozapine, Neutropenia, Antipsychotic Agents, Delivery of Health Care, Integrated. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: TPMG Delivery Science and Applied Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Clozapine, a highly effective antipsychotic medication, is associated with rare but potentially life‐threatening neutropenia. In February 2025, the US Food and Drug Administration (FDA) eliminated its clozapine Risk Evaluation and Mitigation Strategies (REMS) program, which required documented absolute neutrophil count (ANC) lab results prior to clozapine dispensation. Considering the FDA decision, the purpose of this study was to examine the prevalence and patient‐level factors associated with clozapine‐associated neutropenia in a large, diverse, US‐based integrated health system.

Methods

This was a retrospective cohort study of adult Kaiser Permanente Northern California members who initiated clozapine therapy between January 2021 and December 2022. Data were extracted from KPNC's electronic health record, including sociodemographic and clinical characteristics, medication fills, and ANC values. The main outcome was any neutropenic event within two years of clozapine initiation, classified as mild (ANC = 1000–1499/μL) or severe (ANC < 1000/μL).

Results

Among 402 patients, 10 (2.5%) experienced neutropenia within 24 months of starting clozapine. Eight cases were mild, and two were severe, with one resulting in death. Race differed significantly between those who experienced neutropenia and those who did not ( p = 0.038). The mean clozapine dose at the time of neutropenia was 192.5 mg, with significant differences between mild and severe cases ( p = 0.015). Logistic regression analyses showed no significant associations between neutropenia and patient‐level sociodemographic or clinical characteristics.

Conclusion

Clozapine‐related neutropenia was rare and typically transient, but it can be life‐threatening. Continued adherence to the manufacturer's recommendations for ANC monitoring is warranted to ensure patient safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClozapineNeutropeniaAntipsychotic AgentsDelivery of Health Care, IntegratedHumansMaleFemaleRetrospective StudiesMiddle AgedAdultPrevalenceCaliforniaAgedYoung AdultRisk Factors

Stichwörter der Autor:innen

REMSabsolute neutrophil countadverse drug reactionsagranulocytosisantipsychoticmental healthpharmacovigilance

Substanzen

ClozapineAntipsychotic Agents

Autor:innen und Institutionen

  • Regional Clinical Pharmacy Operations, Kaiser Permanente Northern California, Livermore, California, USA.
  • Division of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
  • Clinical Pharmacy Operations, Kaiser Permanente Greater San Jose Area, San Jose, California, USA.
  • Department of Psychiatry, Kaiser Permanente Oakland Medical Center, Oakland, California, USA.
  • Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, California, USA.
  • Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California, USA.

ORCID-Profile: Jill L Nofziger

Förderung

  • TPMG Delivery Science and Applied Research Program

Zitieren

APA

Nofziger, J. L., Kline-Simon, A. H., Arnbrecht, L. M., Durojaiye, C., & Hirschtritt, M. E. (2025). Clozapine‐Associated Neutropenia Prevalence in a Large, Integrated Healthcare System. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70249

Vancouver

Nofziger JL, Kline-Simon AH, Arnbrecht LM, Durojaiye C, Hirschtritt ME. Clozapine‐Associated Neutropenia Prevalence in a Large, Integrated Healthcare System. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70249

BibTeX
@article{Nofziger2025,
  author = {Nofziger, Jill L and Kline-Simon, Andrea H and Arnbrecht, Leah M and Durojaiye, Cimone and Hirschtritt, Matthew E},
  title = {Clozapine‐Associated Neutropenia Prevalence in a Large, Integrated Healthcare System},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2025},
  doi = {10.1002/pds.70249}
}
Kostenlos starten →